What is it about?

The aim of the present study was to introduction of hydroxyapatite/chitosan nanocomposite as a new radiosynovectomy agent with excellent properties.

Featured Image

Why is it important?

the prepared radiopharmaceutical would be a potential therapeutic agent for use in radiosynovectomy procedure.


Because the natural bone is composed of both organic component (biopolymer) and inorganic component (HA), the preparation of inorganic-organic hybrid nanocomposites can be a mimic of the complex nanostructured architecture of bone [20]. Among biodegradabe polymers, chitosan (CS) can be an ideal candidate due to its unique properties such as bioactivity, biodegradability, biocompatibility, solubility in an aqueous medium and the ability to form complexes. Combination of CS with nHA and formation of HA/CS nanocomposite can improve the mechanical strength of pure nHA without affecting its biodegradability and biocompatibility properties. The main objective of this work is the preparation and characterization of HA/CS nanocomposite radiolabelled with 153Sm as a new radiopharmaceutical for use in radiosynovectomy.

Robabeh Alizadeh
Damghan University

Read the Original

This page is a summary of: Design, synthesis and characterization of hydroxyapatite-chitosan nanocomposite radiolabelled with 153Sm as radiopharmaceutical for use in radiosynovectomy, Radiochimica Acta, December 2019, De Gruyter,
DOI: 10.1515/ract-2018-3038.
You can read the full text:



The following have contributed to this page